Financial Data and Key Metrics - The company reported Q3 2024 revenues of $4.9 billion, with 1% organic revenue growth, in line with expectations [11] - Adjusted EBIT margin was 16.3%, up 90 basis points year-over-year, and adjusted EPS was $1.14, up 15% year-over-year [13] - Free cash flow was $651 million, up $81 million year-over-year [13] - The company raised the low-end of its full-year adjusted EBIT margin guidance to 15.8%-16% and adjusted EPS guidance to $4.25-$4.35 per share [27] Business Line Performance - Imaging segment organic revenue was down 1% year-over-year due to headwinds in China, partially offset by strength in the U.S. [18] - Advanced Visualization Solutions segment organic revenue was flat year-over-year, with increased U.S. sales offset by a decrease in China [19] - Patient Care Solutions segment organic revenue was up 2% year-over-year, driven by backlog execution [20] - Pharmaceutical Diagnostics segment delivered 7% year-over-year organic growth, driven by healthy procedure volumes [21] Market Performance - Excluding China, global sales growth was approximately 5%, and orders growth was 4% [11] - The U.S. market showed strong performance across all segments, with multiyear enterprise deals driving orders and sales [7] - China market recovery has been slow, with sales down 17% year-to-date, impacting total company sales growth by approximately 400 basis points [11][42] Company Strategy and Industry Competition - The company is focusing on innovation, particularly in Theranostics, with advancements in molecular imaging and FDA clearance for a new software tool to standardize radiation dosage measurement [10] - Investments in AI and cloud-based solutions are being made to address customer data overload and operational inefficiencies [30] - The company is optimizing its cost structure through lean initiatives and IT transformation, with expected annual savings of $4 million from software license alignment [16] Management Commentary on Operating Environment and Future Outlook - Management views the China market challenges as temporary and remains optimistic about the mid to long-term attractiveness of the market [8][41] - The company is confident in its fundamentals, supported by innovation, a strong backlog, and operational focus [32] - The company expects limited market benefit from China's stimulus through the first half of 2025 [25] Other Important Information - The company has exited the majority of Transition Service Agreements (TSAs) and is on track to exit the remaining agreements on time, positioning it well for further cost optimization [16] - The company announced Flyrcado, an FDA-approved F-18 PET myocardial perfusion imaging tracer, expected to become commercially available in the U.S. in early 2025 [28] Q&A Session Summary Question: Margins and future operating margin expansion [34] - The company has delivered strong margin performance year-to-date, with EBIT margin up 70 basis points and gross margin up 130 basis points [35] - Future margin improvements will be driven by continued focus on price, productivity initiatives, and the benefits of R&D investments [37] Question: China market trajectory and impact on sales growth [38] - The China market recovery is slow, with limited improvement expected through the first half of 2025 [39][41] - The company expects China sales to be down high teens for the full year 2024 [42] Question: Pricing and growth assumptions for 2025 [50] - The company expects pricing to follow new product introductions, with positive sales price trends in the quarter [51] - R&D investments are expected to normalize to more sustainable growth rates in 2025 [71] Question: Flyrcado pricing and market potential [46] - Flyrcado is expected to command a premium due to its improved specificity, sensitivity, and operational capabilities [47] - The company estimates potential annual revenues of over $500 million from Flyrcado once the health system infrastructure is in place [29] Question: Infrastructure requirements for Flyrcado [55] - Flyrcado requires PET systems, which may need to be acquired and installed in cardiology areas, with shared use systems expected in some institutions [57] Question: Vizamyl performance and CMS reimbursement impact [55] - Vizamyl sales in the U.S. nearly doubled quarter-over-quarter, with potential for further growth due to CMS reimbursement changes [59] Question: Pharmaceutical Diagnostics business components and growth levers [64] - The Pharmaceutical Diagnostics business includes proprietary molecules, equipment, and digital integration, with growth driven by new agents, reimbursement changes, and integrated solutions [66][68] Question: 2025 P&L building blocks and one-time items [69] - R&D growth is expected to normalize, and SG&A is expected to move with sales, with no dramatic one-time step-up in incentive compensation expected [71] Question: China's impact on 2025 growth and margin progression [73] - The company is cautious about China's recovery timing and will provide more detailed guidance in February [74] - Mid-single-digit organic revenue growth and margin expansion are expected in the medium term [74][77] Question: Q4 organic growth and confidence in sequential ramp [78] - Q4 organic growth is expected to be slightly above 2%, driven by strength in PDx, service business, and the U.S. market [79] - The company has good visibility into backlog conversion and expects similar conversion rates to historical levels [81] Question: Flyrcado market penetration and system-side impact [83] - Flyrcado's market penetration will depend on the availability of PET systems, with potential for significant conversion over a three to five-year horizon [84] - Flyrcado is expected to drive PET system sales and strengthen the company's position in the molecular imaging market [85] Question: China market steps and Flyrcado launch preparation [89] - The China market is in the first step of recovery, with funds not yet released and tenders not opened [90] - Flyrcado launch preparations include working with CMS for reimbursement and commercialization ramp-up, with expected commercialization in late Q1 2025 [90]

For the quarter ended September 2024, GE HealthCare Technologies (GEHC) reported revenue of $4.86 billion, up 0.9% over the same period last year. EPS came in at $1.14, compared to $0.99 in the year-ago quarter.The reported revenue represents a surprise of -0.02% over the Zacks Consensus Estimate of $4.86 billion. With the consensus EPS estimate being $1.06, the EPS surprise was +7.55%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations t ...

Key Takeaways GE HealthCare shares rose Wednesday morning after the former General Electric Segment posted a thirdquarter earnings beat. Revenue was roughly in line with estimates, nearly flat year-over-year as the company said sales weakness in China has continued. Profits grew 25% from last year, as CEO Peter Arduini said the company's "ongoing lean initiatives" are boosting profit margins. GE HealthCare (GEHC) reported better profits than expected for the third quarter as its sales were roughly in line w ...

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $0.99 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 7.55%. A quarter ago, it was expected that this medical technology company would post earnings of $0.98 per share when it actually produced earnings of $1, delivering a surprise of 2.04%. Over the last ...

3Q 2024 Earnings Presentation October 30, 2024 © 2024 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Forward-looking statements and additional information This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "plan," "believe," "anticipate," "intend," "estimate," "potential," "position," "forecast," "target," "guidance," "outl ...

Financial Performance - Revenue increased by 15% compared to the previous quarter [1]. - Net profit margin improved to 12%, up from 10% last year [2]. - Operating expenses rose by 8% due to increased marketing efforts [3]. - Earnings per share (EPS) reached $1.50, surpassing analyst expectations [4]. Operational Highlights - The company expanded its market share in Asia by 5% [1]. - A new production facility was inaugurated, increasing capacity by 20% [2]. - Customer retention rate improved to 85%, up from 80% [3]. - Supply chain disruptions were minimized, ensuring timely deliveries [4]. Strategic Initiatives - Launched a new product line targeting the premium segment [1]. - Entered into a strategic partnership with a leading tech firm [2]. - Invested $50 million in R&D to drive innovation [3]. - Announced plans to expand into two new international markets [4]. Risk Factors - Rising raw material costs could impact future profitability [1]. - Regulatory changes in key markets may pose challenges [2]. - Increased competition in the industry could pressure margins [3]. - Potential economic slowdowns in major markets remain a concern [4]. Corporate Governance - Appointed two new independent directors to the board [1]. - Enhanced ESG (Environmental, Social, and Governance) initiatives [2]. - Conducted a comprehensive review of internal controls [3]. - Shareholders approved a new executive compensation plan [4].

Exhibit 99 GE HealthCare reports third quarter 2024 financial results • Revenue growth was 1% year-over-year; Organic revenue growth* was 1% • Net income margin was 9.7% versus 7.8% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 16.3% versus 15.4% • Diluted earnings per share (EPS) were $1.02 versus $0.83 for the prior year; Adjusted EPS* was $1.14 versus $0.99 • Cash flow from operating activities was $742 million versus $650 million for the prior year; Free cash flow* w ...

Investors interested in Medical Info Systems stocks are likely familiar with Definitive Healthcare Corp. (DH) and GE HealthCare Technologies (GEHC) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores ...

GE HealthCare Technologies Inc. (GEHC) is scheduled to report third-quarter 2024 results on Oct. 30, before market open. In the last reported quarter, the company's adjusted earnings per share of $1 beat the Zacks Consensus Estimate by 0.27%. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Let's take a look at how things might have shaped up for GEHC prior to the announcement. Factors at Play GE HealthCare's performance is expected to have been hurt by a lower volume of sales durin ...

Core Viewpoint - GE HealthCare Technologies (GEHC) has launched CareIntellect for Oncology, a cloud-first application that integrates multi-modal patient data using generative AI to enhance clinical decision-making and patient care. Group 1: Product Launch and Features - CareIntellect for Oncology will initially focus on breast and prostate cancer, providing a comprehensive view of patient data to streamline treatment assessments and clinical trial eligibility [1][4] - The application organizes both structured and unstructured data, reducing the time clinicians spend on gathering patient histories from multiple systems [2][3] - It will be available to U.S. consumers in 2025, with plans for expansion to Canada, the UK, and Ireland [4] Group 2: Market Performance and Financials - Following the announcement, GEHC shares fell by 1.7% to $89.80, but have increased by 16.2% year-to-date, outperforming the industry which declined by 9.6% [2] - GEHC has a market capitalization of $41.01 billion and an earnings yield of 4.74%, significantly higher than the industry's negative yield of 8.78% [2] Group 3: Industry Trends and Opportunities - The global generative AI in healthcare market is projected to grow from $1.6 billion in 2022 to over $30.4 billion by 2032, with a CAGR of 34.9% [5] - The increasing volume of healthcare data and the shortage of healthcare workers are driving the adoption of AI solutions in clinical settings [5] Group 4: Recent Developments in AI - GEHC has launched Versana Premier, an AI-enabled ultrasound system, and acquired Intelligent Ultrasound Group PLC's clinical AI software business to enhance its ultrasound portfolio [6] - The company also introduced Venue Sprint, a portable ultrasound system designed for point-of-care use, equipped with advanced AI tools [6][7]